{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:19:33Z","timestamp":1792448373531,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-022-01306-6","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T12:26:28Z","timestamp":1675167988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus"],"prefix":"10.1038","author":[{"given":"Laura P.","family":"Kincer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Beth","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Gilleece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake M.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Di Germanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-9563","authenticated-orcid":false,"given":"Dietmar","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-747X","authenticated-orcid":false,"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Spudich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gisslen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-6044","authenticated-orcid":false,"given":"Richard W.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-0773","authenticated-orcid":false,"given":"Ronald","family":"Swanstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.1128\/JVI.03577-12","volume":"87","author":"LH Ping","year":"2013","unstructured":"Ping, L. H. et al. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J. Virol. 87, 7218\u20137233 (2013).","journal-title":"J. Virol."},{"key":"1306_CR2","doi-asserted-by":"publisher","first-page":"e1002686","DOI":"10.1371\/journal.ppat.1002686","volume":"8","author":"NF Parrish","year":"2012","unstructured":"Parrish, N. F. et al. Transmitted\/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin \u03b14\u03b27. PLoS Pathog. 8, e1002686 (2012).","journal-title":"PLoS Pathog."},{"key":"1306_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/JLB.2RI0517-200R","volume":"103","author":"SB Joseph","year":"2018","unstructured":"Joseph, S. B. & Swanstrom, R. The evolution of HIV-1 entry phenotypes as a guide to changing target cells. J. Leuk. Biol. 103, 421\u2013431 (2018).","journal-title":"J. Leuk. Biol."},{"key":"1306_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","volume":"24","author":"DJ Colby","year":"2018","unstructured":"Colby, D. J. et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med. 24, 923\u2013926 (2018).","journal-title":"Nat. Med."},{"key":"1306_CR5","doi-asserted-by":"publisher","first-page":"e1002417","DOI":"10.1371\/journal.pmed.1002417","volume":"14","author":"TJ Henrich","year":"2017","unstructured":"Henrich, T. J. et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med. 14, e1002417 (2017).","journal-title":"PLoS Med."},{"key":"1306_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature13594","volume":"512","author":"JB Whitney","year":"2014","unstructured":"Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74\u201377 (2014).","journal-title":"Nature"},{"key":"1306_CR7","first-page":"310","volume":"72","author":"GC Treasure","year":"2016","unstructured":"Treasure, G. C. et al. Relationship among viral load outcomes in HIV treatment interruption trials. J. Acquir. Immune Defic. Syndr. 72, 310\u2013313 (2016).","journal-title":"J."},{"key":"1306_CR8","first-page":"343","volume":"30","author":"JZ Li","year":"2016","unstructured":"Li, J. Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343\u2013353 (2016).","journal-title":"AIDS"},{"key":"1306_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/infdis\/jiw172","volume":"214","author":"MM Bednar","year":"2016","unstructured":"Bednar, M. M. et al. Diversity and tropism of HIV-1 rebound virus populations in plasma level after treatment discontinuation. J. Infect. Dis. 214, 403\u2013407 (2016).","journal-title":"J. Infect. Dis."},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.chom.2019.08.003","volume":"26","author":"MA De Scheerder","year":"2019","unstructured":"De Scheerder, M. A. et al. HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs. Cell Host Microbe 26, 347\u2013358 (2019).","journal-title":"Cell Host Microbe"},{"key":"1306_CR12","doi-asserted-by":"publisher","first-page":"e0201121","DOI":"10.1128\/jvi.02011-21","volume":"96","author":"K Fisher","year":"2022","unstructured":"Fisher, K. et al. Plasma-derived HIV-1 virions contain considerable levels of defective genomes. J. Virol. 96, e0201121 (2022).","journal-title":"J. Virol."},{"key":"1306_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1128\/JVI.02139-15","volume":"90","author":"MF Kearney","year":"2016","unstructured":"Kearney, M. F. et al. Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy. J. Virol. 90, 1369\u20131376 (2016).","journal-title":"J. Virol."},{"key":"1306_CR14","doi-asserted-by":"publisher","first-page":"E1126","DOI":"10.1073\/pnas.1414926112","volume":"112","author":"MK Rothenberger","year":"2015","unstructured":"Rothenberger, M. K. et al. Large number of rebounding\/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc. Natl Acad. Sci. USA 112, E1126\u2013E1134 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1306_CR15","doi-asserted-by":"publisher","first-page":"9981","DOI":"10.1073\/pnas.1917034117","volume":"117","author":"VM Andrade","year":"2020","unstructured":"Andrade, V. M. et al. A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proc. Natl Acad. Sci. USA 117, 9981\u20139990 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1306_CR16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/nm1295-1284","volume":"1","author":"TW Chun","year":"1995","unstructured":"Chun, T. W. et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1, 1284\u20131290 (1995).","journal-title":"Nat. Med."},{"key":"1306_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.celrep.2017.09.081","volume":"21","author":"B Hiener","year":"2017","unstructured":"Hiener, B. et al. Identification of genetically intact HIV-1 proviruses in specific CD4+ T cells from effectively treated participants. Cell Rep. 21, 813\u2013822 (2017).","journal-title":"Cell Rep."},{"key":"1306_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893\u2013900 (2009).","journal-title":"Nat. Med."},{"key":"1306_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11904-020-00481-7","volume":"17","author":"BL Shacklett","year":"2020","unstructured":"Shacklett, B. L., Ferre, A. L. & Kiniry, B. E. Defining T cell tissue residency in humans: implications for HIV pathogenesis and vaccine design. Curr. HIV\/AIDS Rep. 17, 109\u2013117 (2020).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"1306_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.it.2015.08.006","volume":"36","author":"A Louveau","year":"2015","unstructured":"Louveau, A., Harris, T. H. & Kipnis, J. Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 36, 569\u2013577 (2015).","journal-title":"Trends Immunol."},{"key":"1306_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ni.3666","volume":"18","author":"B Engelhardt","year":"2017","unstructured":"Engelhardt, B., Vajkoczy, P. & Weller, R. O. The movers and shapers in immune privilege of the CNS. Nat. Immunol. 18, 123\u2013131 (2017).","journal-title":"Nat. Immunol."},{"key":"1306_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.molmed.2017.01.004","volume":"23","author":"A Iwasaki","year":"2017","unstructured":"Iwasaki, A. Immune regulation of antibody access to neuronal tissues. Trends Mol. Med. 23, 227\u2013245 (2017).","journal-title":"Trends Mol. Med."},{"key":"1306_CR23","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1093\/infdis\/jix662","volume":"217","author":"PD Burbelo","year":"2018","unstructured":"Burbelo, P. D. et al. Anti-human immunodeficiency virus antibodies in the cerebrospinal fluid: evidence of early treatment impact on central nervous system reservoir? J. Infect. Dis. 217, 1024\u20131032 (2018).","journal-title":"J. Infect. Dis."},{"key":"1306_CR24","doi-asserted-by":"publisher","first-page":"e1004720","DOI":"10.1371\/journal.ppat.1004720","volume":"11","author":"CB Sturdevant","year":"2015","unstructured":"Sturdevant, C. B. et al. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog. 11, e1004720 (2015).","journal-title":"PLoS Pathog."},{"key":"1306_CR25","doi-asserted-by":"publisher","first-page":"e1002286","DOI":"10.1371\/journal.ppat.1002286","volume":"7","author":"G Schnell","year":"2011","unstructured":"Schnell, G. et al. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 7, e1002286 (2011).","journal-title":"PLoS Pathog."},{"key":"1306_CR26","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1128\/JVI.02477-13","volume":"88","author":"SB Joseph","year":"2014","unstructured":"Joseph, S. B. et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J. Virol. 88, 1858\u20131869 (2014).","journal-title":"J. Virol."},{"key":"1306_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/jnv.10.s1.44.51","volume":"10","author":"RW Price","year":"2004","unstructured":"Price, R. W. & Deeks, S. G. Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: clinical and pathogenetic implications for the central nervous system. J. NeuroVirol. 10, 44\u201351 (2004).","journal-title":"J. NeuroVirol."},{"key":"1306_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nmeth.3320","volume":"12","author":"PJ Santangelo","year":"2015","unstructured":"Santangelo, P. J. et al. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat. Methods 12, 427\u2013432 (2015).","journal-title":"Nat. Methods"},{"key":"1306_CR29","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1172\/JCI98968","volume":"128","author":"JB Honeycutt","year":"2018","unstructured":"Honeycutt, J. B. et al. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J. Clin. Invest. 128, 2862\u20132876 (2018).","journal-title":"J. Clin. Invest."},{"key":"1306_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm.4319","volume":"23","author":"JB Honeycutt","year":"2017","unstructured":"Honeycutt, J. B. et al. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat. Med. 23, 638\u2013643 (2017).","journal-title":"Nat. Med."},{"key":"1306_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07881-9","volume":"9","author":"JB Whitney","year":"2018","unstructured":"Whitney, J. B. et al. Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat. Commun. 9, 5429 (2018).","journal-title":"Nat. Commun."},{"key":"1306_CR32","doi-asserted-by":"publisher","first-page":"e1006359","DOI":"10.1371\/journal.ppat.1006359","volume":"13","author":"CM Fennessey","year":"2017","unstructured":"Fennessey, C. M. et al. Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathog. 13, e1006359 (2017).","journal-title":"PLoS Pathog."},{"key":"1306_CR33","doi-asserted-by":"publisher","first-page":"e152526","DOI":"10.1172\/jci.insight.152526","volume":"6","author":"V Obregon-Perko","year":"2021","unstructured":"Obregon-Perko, V. et al. Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART. JCI Insight 6, e152526 (2021).","journal-title":"JCI Insight"},{"key":"1306_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/QAD.0000000000001267","volume":"31","author":"L Gama","year":"2017","unstructured":"Gama, L. et al. Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. AIDS 31, 5\u201314 (2017).","journal-title":"AIDS"},{"key":"1306_CR35","doi-asserted-by":"publisher","first-page":"e01186","DOI":"10.1128\/mBio.01186-17","volume":"8","author":"CR Avalos","year":"2017","unstructured":"Avalos, C. R. et al. Brain macrophages in simian immunodeficiency virus-infected, antiretroviral-suppressed macaques: a functional latent reservoir. mBio 8, e01186-17 (2017).","journal-title":"mBio"},{"key":"1306_CR36","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1097\/QAD.0000000000002269","volume":"33","author":"C Abreu","year":"2019","unstructured":"Abreu, C. et al. Brain macrophages harbor latent, infectious simian immunodeficiency virus. AIDS 33, S181\u2013S188 (2019).","journal-title":"AIDS"},{"key":"1306_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11481-021-10011-w","volume":"16","author":"H Su","year":"2021","unstructured":"Su, H. et al. Recovery of latent HIV-1 from brain tissue by adoptive cell transfer in virally suppressed humanized mice. J. Neuroimmune Pharmacol. 16, 796\u2013805 (2021).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"1306_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-018-0321-2","volume":"19","author":"K Dub\u00e9","year":"2018","unstructured":"Dub\u00e9, K. et al. Ethical considerations for HIV cure-related research at the end of life. BMC Med. Ethics 19, 83 (2018).","journal-title":"BMC Med. Ethics"},{"key":"1306_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jneuroim.2005.07.012","volume":"169","author":"SN de Almeida","year":"2005","unstructured":"de Almeida, S. N. et al. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J. Neuroimmunol. 169, 144\u2013152 (2005).","journal-title":"J. Neuroimmunol."},{"key":"1306_CR40","doi-asserted-by":"publisher","first-page":"vew020","DOI":"10.1093\/ve\/vew020","volume":"2","author":"S Gianella","year":"2016","unstructured":"Gianella, S. et al. Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy. Virus Evol. 2, vew020 (2016).","journal-title":"Virus Evol."},{"key":"1306_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJM200102153440702","volume":"344","author":"SG Deeks","year":"2001","unstructured":"Deeks, S. G. et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344, 472\u2013480 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR42","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/00002030-200107060-00006","volume":"15","author":"RW Price","year":"2001","unstructured":"Price, R. W. et al. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15, 1251\u20131259 (2001).","journal-title":"AIDS"},{"key":"1306_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-2-6","volume":"2","author":"M Gisslen","year":"2005","unstructured":"Gisslen, M. et al. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res. Ther. 2, 6 (2005).","journal-title":"AIDS Res. Ther."},{"key":"1306_CR44","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1128\/JVI.00441-16","volume":"90","author":"S Zhou","year":"2016","unstructured":"Zhou, S. et al. Deep sequencing of the HIV-1 env gene reveals discrete X4 lineages and linkage disequilibrium between X4 and R5 viruses in the V1\/V2 and V3 variable regions. J. Virol. 90, 7142\u20137158 (2016).","journal-title":"J. Virol."},{"key":"1306_CR45","doi-asserted-by":"publisher","first-page":"8540","DOI":"10.1128\/JVI.00522-15","volume":"89","author":"S Zhou","year":"2015","unstructured":"Zhou, S. et al. Primer ID validates template sampling depth and greatly reduces the error rate of next-generation sequencing of HIV-1 genomic RNA populations. J. Virol. 89, 8540\u20138555 (2015).","journal-title":"J. Virol."},{"key":"1306_CR46","doi-asserted-by":"publisher","first-page":"e1009871","DOI":"10.1371\/journal.ppat.1009871","volume":"17","author":"G Lustig","year":"2021","unstructured":"Lustig, G. et al. T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy. PLoS Pathog. 17, e1009871 (2021).","journal-title":"PLoS Pathog."},{"key":"1306_CR47","doi-asserted-by":"publisher","first-page":"e1010105","DOI":"10.1371\/journal.ppat.1010105","volume":"17","author":"V Sharma","year":"2021","unstructured":"Sharma, V. et al. Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1. PLoS Pathog. 17, e1010105 (2021).","journal-title":"PLoS Pathog."},{"key":"1306_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/genetics\/123.3.603","volume":"123","author":"M Slatkin","year":"1989","unstructured":"Slatkin, M. & Maddison, W. P. A cladistic measure of gene flow inferred from the phylogenies of alleles. Genetics 123, 603\u2013613 (1989).","journal-title":"Genetics"},{"key":"1306_CR49","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1089\/aid.2019.0245","volume":"36","author":"OM Adewumi","year":"2020","unstructured":"Adewumi, O. M. et al. HIV-1 central nervous system compartmentalization and cytokine interplay in non-subtype B HIV-1 infections in Nigeria and Malawi. AIDS Res. Hum. Retroviruses 36, 490\u2013500 (2020).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1306_CR50","doi-asserted-by":"publisher","first-page":"e1008791","DOI":"10.1371\/journal.ppat.1008791","volume":"16","author":"HA Aamer","year":"2020","unstructured":"Aamer, H. A. et al. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment. PLoS Pathog. 16, e1008791 (2020).","journal-title":"PLoS Pathog."},{"key":"1306_CR51","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1128\/JVI.00591-06","volume":"80","author":"JR Bailey","year":"2006","unstructured":"Bailey, J. R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4(+) T cells. J. Virol. 80, 6441\u20136457 (2006).","journal-title":"J. Virol."},{"key":"1306_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24080-1","volume":"12","author":"B Cole","year":"2021","unstructured":"Cole, B. et al. In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. Nat. Commun. 12, 3727 (2021).","journal-title":"Nat. Commun."},{"key":"1306_CR53","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1172\/JCI138099","volume":"130","author":"EK Halvas","year":"2020","unstructured":"Halvas, E. K. et al. HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. J. Clin. Invest. 130, 5847\u20135857 (2020).","journal-title":"J. Clin. Invest."},{"key":"1306_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12985-016-0617-0","volume":"13","author":"S Rassler","year":"2016","unstructured":"Rassler, S. et al. Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy. Virol. J. 13, 157 (2016).","journal-title":"Virol. J."},{"key":"1306_CR55","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.1128\/JVI.00362-10","volume":"84","author":"GK Sahu","year":"2010","unstructured":"Sahu, G. K., Sarria, J. C. & Cloyd, M. W. Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J. Virol. 84, 8348\u20138352 (2010).","journal-title":"J. Virol."},{"key":"1306_CR56","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1073\/pnas.1522675113","volume":"113","author":"FR Simonetti","year":"2016","unstructured":"Simonetti, F. R. et al. Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc. Natl Acad. Sci. USA 113, 1883\u20131888 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1306_CR57","doi-asserted-by":"publisher","first-page":"E11341","DOI":"10.1073\/pnas.1813512115","volume":"115","author":"CL Lu","year":"2018","unstructured":"Lu, C. L. et al. Relationship between intact HIV-1 proviruses in circulating CD4(+) T cells and rebound viruses emerging during treatment interruption. Proc. Natl Acad. Sci. USA 115, E11341\u2013E11348 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1306_CR58","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1084\/jem.20180936","volume":"215","author":"YZ Cohen","year":"2018","unstructured":"Cohen, Y. Z. et al. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J. Exp. Med. 215, 2311\u20132324 (2018).","journal-title":"J. Exp. Med."},{"key":"1306_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19254-2","volume":"11","author":"PT Liu","year":"2020","unstructured":"Liu, P. T. et al. Origin of rebound virus in chronically SIV-infected rhesus monkeys following treatment discontinuation. Nat. Commun. 11, 5412 (2020).","journal-title":"Nat. Commun."},{"key":"1306_CR60","doi-asserted-by":"publisher","first-page":"11016","DOI":"10.1128\/JVI.01242-09","volume":"83","author":"SH Johnston","year":"2009","unstructured":"Johnston, S. H. et al. A quantitative affinity-profiling system that reveals distinct CD4\/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol. 83, 11016\u201311026 (2009).","journal-title":"J. Virol."},{"key":"1306_CR61","doi-asserted-by":"publisher","first-page":"eaaw5589","DOI":"10.1126\/scitranslmed.aaw5589","volume":"11","author":"MR Abrahams","year":"2019","unstructured":"Abrahams, M. R. et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci. Transl. Med. 11, eaaw5589 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1306_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1086\/317641","volume":"183","author":"H Imamichi","year":"2001","unstructured":"Imamichi, H. et al. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J. Infect. Dis. 183, 36\u201350 (2001).","journal-title":"J. Infect. Dis."},{"key":"1306_CR63","doi-asserted-by":"publisher","first-page":"e1004010","DOI":"10.1371\/journal.ppat.1004010","volume":"10","author":"MF Kearney","year":"2014","unstructured":"Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).","journal-title":"PLoS Pathog."},{"key":"1306_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-7-15","volume":"7","author":"L Hagberg","year":"2010","unstructured":"Hagberg, L. et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res. Ther. 7, 15 (2010).","journal-title":"AIDS Res. Ther."},{"key":"1306_CR65","doi-asserted-by":"publisher","first-page":"e88591","DOI":"10.1371\/journal.pone.0088591","volume":"9","author":"J Jessen Krut","year":"2014","unstructured":"Jessen Krut, J. et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS ONE 9, e88591 (2014).","journal-title":"PLoS ONE"},{"key":"1306_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","volume":"987","author":"N Norgren","year":"2003","unstructured":"Norgren, N., Rosengren, L. & Stigbrand, T. Elevated neurofilament levels in neurological diseases. Brain Res. 987, 25\u201331 (2003).","journal-title":"Brain Res."},{"key":"1306_CR67","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz, A. et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev. Mol. Diagn. 17, 761\u2013770 (2017).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1306_CR68","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/nar\/gkh340","volume":"32","author":"RC Edgar","year":"2004","unstructured":"Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792\u20131797 (2004).","journal-title":"Nucleic Acids Res."},{"key":"1306_CR69","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.21769\/BioProtoc.1184","volume":"4","author":"SB Joseph","year":"2014","unstructured":"Joseph, S. B., Lee, B. & Swanstrom, R. Affinofile assay for identifying macrophage-tropic HIV-1. Bio Protoc. 4, e1184 (2014).","journal-title":"Bio Protoc."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01306-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01306-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01306-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T14:22:09Z","timestamp":1683814929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01306-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":69,"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1038\/s41564-022-01306-6","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UNC is pursuing IP protection for Primer ID and R.S. has received nominal royalties.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}